Amy Q. Wang

2.6k citations

31 papers · 1.1k · h-index 17

Impact in

Endocrinology, Diabetes and Metabolism top 5%
- Diabetes Treatment and Management
Biological Psychiatry top 10%

Papers in

Molecular Biology 11
- Protein Degradation and Inhibitors 2
Infectious Diseases 8
- HIV/AIDS drug development and treatment 6

Co-authors: Xin Xu (21 shared papers)Gary Herman (3 shared papers)Wei Zeng (3 shared papers)Karen Snyder (3 shared papers)John A. Wagner (3 shared papers)Li Chen (3 shared papers)Arthur Bergman (3 shared papers)Deborah Hilliard (2 shared papers)
Journals: Journal of Medicinal Chemistry (5 papers)Frontiers in Pharmacology (3 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)ACS Chemical Neuroscience (1 paper)Journal of Psychopharmacology (1 paper)
Partner nations: United States United Kingdom Czechia

In The Last Decade

Amy Q. Wang

29 papers receiving 1.0k citations

Peers

Countries citing papers authored by Amy Q. Wang

Since Specialization

Citations

This map shows the geographic impact of Amy Q. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Q. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Q. Wang more than expected).

Fields of papers citing papers by Amy Q. Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Q. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Q. Wang. The network helps show where Amy Q. Wang may publish in the future.

Co-authors

The 25 scholars most cited alongside Amy Q. Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amy Q. Wang Line = papers co-authored together Amy Q. Wang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers Clinical Therapeutics ·Arthur Bergman, Catherine Stevens, Yanyan Zhou, Bingming Yi, Martine E. Laethem, Marina De Smet, Karen Snyder, Deborah Hilliard, Wesley Tanaka, Wei Zeng, Michael Tanen, Amy Q. Wang, Li Chen, Gregory A. Winchell, Michael J. Davies, Steven Ramael, John A. Wagner, Gary Herman	2006	220
2	Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects The Journal of Clinical Pharmacology ·Gary Herman, Arthur Bergman, Fang Liu, Cathy Stevens, Amy Q. Wang, Wei Zeng, Li Chen, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka, Alan G. Meehan, Kenneth C. Lasseter, Stacy C. Dilzer, Robert A. Blum, John A. Wagner	2006	146
3	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection Science Translational Medicine ·Shanshan He, Billy Lin, Virginia Chu, Zongyi Hu, Xin Hu, Jingbo Xiao, Amy Q. Wang, Cameron J. Schweitzer, Qisheng Li, Michio Imamura, Nobuhiko Hiraga, Noel Southall, Marc Ferrer, Wei Zheng, Kazuaki Chayama, Juan Marugán, T. Jake Liang	2015	114
4	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors Journal of Medicinal Chemistry ·Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias Carvalho Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard M. Stone, Gurmit Grewal	2020	71
5	Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity Journal of Medicinal Chemistry ·Shyh‐Ming Yang, Natalia J. Martinez, Adam Yasgar, Carina Danchik, C. Johansson, Yuhong Wang, Bolormaa Baljinnyam, Amy Q. Wang, Xin Xu, Pranav Shah, Dorian M. Cheff, Xinran S. Wang, Jacob S. Roth, Madhu Lal‐Nag, James E. Dunford, Udo Oppermann, Vasilis Vasiliou, Anton Simeonov, Ajit Jadhav, David J. Maloney	2018	70
6	Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus PLoS Pathogens ·Rupkatha Mukhopadhyay, Sujayita Roy, Rajkumar Venkatadri, Yu‐Ping Su, Wenjuan Ye, Elena Barnaeva, Lesley A. Mathews Griner, Noel Southall, Xin Hu, Amy Q. Wang, Xin Xu, Andrés E. Dulcey, Juan Marugán, Marc Ferrer, Ravit Arav‐Boger	2016	46
7	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine Journal of Psychopharmacology ·Jaclyn N. Highland, Patrick J. Morris, Panos Zanos, Jacqueline Lovett, Soumita Ghosh, Amy Q. Wang, Carlos A. Zarate, Craig J. Thomas, Ruin Moaddel, Todd D. Gould	2018	46
8	Safety, pharmacokinetics and sialic acid production after oral administration of N -acetylmannosamine (ManNAc) to subjects with GNE myopathy Molecular Genetics and Metabolism ·Xin Xu, Amy Q. Wang, Lea Latham, Frank Celeste, Carla Ciccone, May Christine V. Malicdan, Barry R. Goldspiel, Pramod Terse, James C. Cradock, N. Nora Yang, Selwyn C. Yorke, John C. McKew, William A. Gahl, Marjan Huizing, Nuria Carrillo	2017	44
9	Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction Biomacromolecules ·Geoffrey M. Lynn, Petr Chytil, Joseph R. Francica, Anna Lagová, Gray Kueberuwa, Andrew S. Ishizuka, Neeha Zaidi, Ramiro A. Ramirez-Valdez, Nicolas J. Blobel, Faezzah Baharom, Joseph M. Leal, Amy Q. Wang, Michael Y. Gerner, Tomáš Etrych, Karel Ulbrich, Leonard W. Seymour, Robert A. Seder, Richard Laga	2019	34
10	Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability Bioorganic & Medicinal Chemistry ·J. W. Williams, Vishal B. Siramshetty, Ðắc-Trung Nguyễn, Elias Carvalho Padilha, Md Kabir, Kyeong Ri Yu, Amy Q. Wang, Tongan Zhao, Misha Itkin, Paul Shinn, Ewy A. Mathé, Xin Xu, Pranav Shah	2022	32
11	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection Journal of Medicinal Chemistry ·Shanshan He, Jingbo Xiao, Andrés E. Dulcey, Billy Lin, Adam Rolt, Zongyi Hu, Xin Hu, Amy Q. Wang, Xin Xu, Noel Southall, Marc Ferrer, Wei Zheng, T. Jake Liang, Juan Marugán	2015	31
12	A rapid and sensitive liquid chromatography/negative ion tandem mass spectrometry method for the determination of an indolocarbazole in human plasma using internal standard (IS) 96‐well diatomaceous earth plates for solid‐liquid extraction Rapid Communications in Mass Spectrometry ·Amy Q. Wang, Wei Zeng, Donald G. Musson, John Rogers, Alison L. Fisher	2002	29
13	Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males British Journal of Clinical Pharmacology ·Gary Herman, Goutam C. Mistry, Bingming Yi, Arthur Bergman, Amy Q. Wang, Wei Zeng, Li Chen, Karen Snyder, Jon Ruckle, Patrick Larson, Michael J. Davies, Ronald B. Langdon, Keith Gottesdiener, John A. Wagner	2010	29
14	Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Jian‐kang Jiang, Xiuli Huang, Khalida Shamim, Paresma Patel, Arthur Lee, Amy Q. Wang, Kimloan Nguyen, Gregory J. Tawa, Gregory D. Cuny, Paul B. Yu, Wei Zheng, Xin Xu, Philip E.J. Sanderson, Wenwei Huang	2018	19
15	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines ACS Chemical Neuroscience ·Jaclyn N. Highland, Patrick J. Morris, Kylie M. Konrath, Lace M. Riggs, Natalie R. Hagen, Panos Zanos, Chris F. Powels, Ruin Moaddel, Craig J. Thomas, Amy Q. Wang, Todd D. Gould	2022	19
16	Development and validation of PAMPA-BBB QSAR model to predict brain penetration potential of novel drug candidates Frontiers in Pharmacology ·Rintaro Kato, Wenyu Zeng, Vishal B. Siramshetty, J. W. Williams, Md Kabir, Natalie R. Hagen, Elias Carvalho Padilha, Amy Q. Wang, Ewy A. Mathé, Xin Xu, Pranav Shah	2023	17
17	Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment Frontiers in Pharmacology ·Amy Q. Wang, Natalie R. Hagen, Elias Carvalho Padilha, Mengbi Yang, Pranav Shah, Catherine Z. Chen, Wenwei Huang, Pramod Terse, Philip E.J. Sanderson, Wei Zheng, Xin Xu	2022	16
18	Discovery and lead identification of quinazoline-based BRD4 inhibitors Bioorganic & Medicinal Chemistry Letters ·Shyh‐Ming Yang, Daniel J. Urban, Makoto Yoshioka, Jeffrey Strovel, Steven Fletcher, Amy Q. Wang, Xin Xu, Pranav Shah, Xin Hu, Matthew D. Hall, Ajit Jadhav, David J. Maloney	2018	13
19	Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection The Journal of Infectious Diseases ·Adam Rolt, Derek J. Le, Zongyi Hu, Amy Q. Wang, Pranav Shah, Marc Singleton, Emma Hughes, Andrés E. Dulcey, Shanshan He, Michio Imamura, Takuro Uchida, Kazuaki Chayama, Xin Xu, Juan Marugán, T. Jake Liang	2018	11
20	Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug Frontiers in Pharmacology ·Mengbi Yang, Amy Q. Wang, Elias Carvalho Padilha, Pranav Shah, Natalie R. Hagen, China Ryu, Khalida Shamim, Wenwei Huang, Xin Xu	2023	9

About Amy Q. Wang

Amy Q. Wang is a scholar working on Molecular Biology, Infectious Diseases, Oncology, Epidemiology and Hepatology, having authored 31 papers that have together received 1.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (6 papers), Hepatitis C virus research (5 papers), Hepatitis B Virus Studies (3 papers), Diabetes Treatment and Management (3 papers), Peptidase Inhibition and Analysis (3 papers), Computational Drug Discovery Methods (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (328 citations), Biological Psychiatry (34 citations), Pharmacology (149 citations), Hepatology (67 citations) and Oncology (225 citations). Amy Q. Wang has collaborated with scholars based in United States, United Kingdom and Czechia. Frequent co-authors include Xin Xu, Gary Herman, Wei Zeng, Karen Snyder, John A. Wagner, Li Chen, Arthur Bergman, Deborah Hilliard, Michael Tanen and Wesley Tanaka. Their work appears in journals such as Journal of Medicinal Chemistry, Frontiers in Pharmacology, Bioorganic & Medicinal Chemistry Letters, ACS Chemical Neuroscience and Journal of Psychopharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Amy Q. Wang

Impact in

Papers in i

In The Last Decade

Amy Q. Wang

Peers

Countries citing papers authored by Amy Q. Wang

Fields of papers citing papers by Amy Q. Wang

All Works

About Amy Q. Wang

Explore authors with similar magnitude of impact

Papers in